查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018726

幽門螺旋桿菌診斷市場：按檢測類型、產品類型、技術和最終用戶分類－2026-2032年全球市場預測

Helicobacter Pylori Diagnostics Market by Test Type, Product Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，幽門螺旋桿菌診斷市場價值將達到 9.0604 億美元，到 2026 年將成長至 9.8187 億美元，到 2032 年將達到 17.7078 億美元，年複合成長率為 10.04%。

主要市場統計數據
基準年 2025 9.0604億美元
預計年份：2026年 9.8187億美元
預測年份 2032 1,770,780,000 美元
複合年成長率 (%) 10.04%

全面概述幽門螺旋桿菌的診斷，重點介紹其臨床意義、診斷方法、患者診療路徑以及在所有醫療保健機構中準確檢測的策略重要性。

幽門螺旋桿菌在慢性胃炎和消化性潰瘍中的重要作用，以及作為胃癌的危險因素，仍然是胃腸病學領域的焦點。因此，準確快速的診斷是臨床上的必要環節，它影響著治療方法的選擇、根除監測以及更廣泛的公共衛生工作。幽門螺旋桿菌的診斷方法包括侵入性和非侵入性兩種途徑，每種方法在敏感性、特異性、結果獲取時間和資源消耗方面各有優劣。

創新的技術、營運和數位轉型正在重塑幽門螺旋桿菌的診斷，影響臨床決策和市場動態。

幽門螺旋桿菌的診斷格局正在經歷快速變革，這主要得益於分子技術的進步、即時檢測設備的微型化以及非侵入性檢測能力的提升。分子診斷平台正從集中式檢查室PCR系統擴展到可在患者床邊進行的等溫PCR方法，以及能夠同時檢測幽門螺旋桿菌和抗生素抗藥性標記的即時PCR設備。同時，改良的免疫檢測和高性能糞便抗原檢測也提高了非侵入性篩檢和治療後確認的準確性。

本研究評估了 2025 年美國關稅措施將如何影響幽門螺旋桿菌診斷產業的供應鏈、製造決策和籌資策略。

美國在2025年實施的關稅對診斷生態系統產生了多方面的影響，波及零件採購、定價策略和供應鏈結構。進口耗材、試劑和分析儀器組件的關稅帶來的成本壓力迫使許多製造商和臨床檢查室重新評估其供應商關係和庫存管理實踐。因此，採購團隊正在延長前置作業時間並增加緩衝庫存，以緩解潛在的供應中斷，這影響了營運資金和營運物流。

基於細分市場的洞察，揭示了測試類型、產品類型、最終用戶需求和技術類別之間的交集，有助於了解診斷技術採用趨勢和投資重點。

透過詳細的細分分析，我們獲得了洞察，揭示了臨床需求與技術能力的交匯點，以及策略性投資能夠帶來最大收益的領域。無論採用何種檢測方法，組織學仍然是侵入性診斷流程的基礎，通常包括蘇木精-伊紅染色以及用於增強病原體可視化的特殊染色。分子檢測的範圍正在不斷擴大，利用等溫擴增技術進行快速的現場檢測，在參考檢查室進行常規聚合酵素鏈鎖反應(PCR) 以進行高靈敏度檢測，以及利用即時PCR對抗藥性標記進行定量和鑑定。快速尿素酶檢測在內鏡檢查室仍然非常有用，目前普遍採用 Clo 檢測和 PyloriTek 檢測的各種變體，這些檢測強調快速性和易於判讀的特點。血清學檢測，例如酵素免疫分析法(ELISA) 和橫向流動化驗，在流行病學研究和某些臨床情況下仍然發揮作用，但作為治療後的確認性檢測，其應用已不如以往廣泛。利用酵素免疫分析法免疫檢測的糞便抗原檢測，有助於進行非侵入性診斷和根除確認。另一方面，尿素呼吸檢測（有<sup>13</sup>C和<sup>14</sup>C兩種版本）仍然是一種高度準確且非侵入性的檢測方法，常用於基層醫療和專科醫療機構。

美洲、歐洲、中東、非洲和亞太地區在診斷趨勢上的區域差異，凸顯了檢測策略的實施現況、基礎設施和政策影響。

區域趨勢對檢測方法的選擇、保險報銷和部署途徑有顯著影響，美洲、歐洲、中東、非洲和亞太地區呈現出不同的模式。在美洲，成熟的檢測網路和先進的報銷機制推動了高靈敏度分子檢測和整合分析平台的應用。中心檢查室和參考檢測服務支援複雜的分子檢測流程，而門診診所和日間護理中心則擴大採用照護現場（POC​​）解決方案，以縮短治療啟動時間。抗菌藥物管理計畫和治療後確認方案也會影響檢測選擇，在該地區同樣至關重要。

從公司層面觀點，重點在於產品表現、夥伴關係模式、供應鏈韌性和臨床證據策略，這些因素決定了幽門螺旋桿菌診斷領域的競爭地位。

診斷領域的競爭格局有利於那些兼具強大的檢測能力、可靠的供應鏈、監管專業知識和清晰的臨床價值提案的公司。成熟的儀器製造商憑藉其現有的儀器基礎設施、服務網路和用於結果管理的整合軟體保持優勢，而敏捷的分子診斷公司則透過快速的檢測開發週期和抗藥性檢測能力脫穎而出。能夠證明其產品在不同檢體類型中具有可重複性，並投資於品質認證的試劑盒和試劑供應商，更有利於與私人實驗室和醫院檢查室簽訂長期合約。

針對診斷設備製造商、檢測實驗室和醫療保健系統，提出具體的策略建議，以促進幽門螺旋桿菌檢測的廣泛應用，提高其韌性，並最大限度地發揮其臨床價值。

產業領導企業應考慮一系列切實可行的措施，以利用新興的診斷趨勢，同時降低營運風險。首先，他們應優先投資於非侵入性分子檢測和高性能抗原檢測，以簡化工作流程並減少對侵入性操作的依賴，同時確保這些檢驗已通過驗證，可用於其預期的臨床用途。其次，他們應透過認證更多供應商、評估近岸外包和區域製造夥伴關係關係來實現供應鏈多元化，從而降低貿易中斷帶來的風險並縮短前置作業時間。

採用綜合混合方法研究途徑，結合專家訪談、工作流程分析、監管審查和技術評估，以檢驗有關診斷的發現和見解。

本分析所依據的研究採用了混合方法，將主要質性研究結果與二手證據和技術評估結合。主要研究包括對臨床醫生、實驗室管理人員、採購負責人和行業高管進行結構化訪談，以了解實際診斷工作流程、採購理由和未滿足的需求。補充的實地考察和工作流程圖繪製則提供了對檢體處理、結果報告以及照護現場(PoC) 系統與檢查室系統之間整合點的背景理解。

對診斷創新、營運韌性和臨床管理的策略整合的明確觀點，塑造了幽門螺旋桿菌檢測的未來。

幽門螺旋桿菌（H. pylori）的診斷正處於一個轉折點，分子診斷能力的提升、非侵入性檢測技術的改進以及臨床路徑的演進共同促成了更精準的患者管理。整個生態系統中的相關人員（包括製造商、檢查室、臨床醫生和醫療保健系統）必須適應技術進步，同時應對供應鏈的複雜性和不斷變化的醫療保險報銷環境。要充分發揮下一代診斷技術的臨床和商業性潛力，需要在產品設計、證據產生和最終用戶需求之間實現策略性協調。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按檢測類型分類的幽門螺旋桿菌診斷市場

  • 組織學
    • 蘇木精-伊紅染色
    • 特殊染色
  • 分子檢測
    • 等溫擴增
    • 聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應
  • 快速尿素酶試驗
    • 交叉測試
    • PyloriTek 檢測
  • 血清學檢測
    • 酵素免疫分析法
    • 橫向流動化驗
  • 糞便抗原檢測
    • 酵素免疫分析法
    • 側向流動免疫檢測
  • 尿素呼吸檢測
    • 13C尿素呼吸檢測
    • 14C尿素呼吸檢測

第9章：幽門螺旋桿菌診斷市場：依產品類型分類

  • 消耗品
    • 成套工具
      • PCR試劑盒
      • 快速尿素酶檢測套組
      • 血清學檢測套組
      • 糞便抗原檢測套組
      • 尿素呼吸檢測試劑盒
    • 試劑
    • 測試條
  • 裝置
    • 分析器
      • 呼吸檢測分析儀
      • 免疫檢測分析儀
      • PCR設備
    • 內視鏡系統

第10章：幽門螺旋桿菌診斷市場：依技術分類

  • 侵入性
    • 文化
    • 組織學
    • 快速尿素酶試驗
  • 非侵入性
    • 抗原檢測
    • 呼吸檢測
      • 糞便抗原檢測
      • 尿素呼吸檢測
    • 分子診斷
    • 血清學

第11章 幽門螺旋桿菌診斷市場：依最終使用者分類

  • 門診部
    • 社區健康中心
    • 門診部
  • 診所
    • 基層醫療診所
    • 專科診所
  • 診斷檢測實驗室
    • 私人考試機構
    • 參考檢測實驗室
  • 醫院
    • 大型醫院
    • 小規模醫院

第12章：幽門螺旋桿菌診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：幽門螺旋桿菌診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：幽門螺旋桿菌診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國幽門螺旋桿菌診斷市場

第16章：中國幽門螺旋桿菌診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alpha Laboratories Ltd.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Certest Biotec SL
  • Coris BioConcept
  • DiaSorin SpA
  • Eiken Chemical Co., Ltd.
  • Epitope Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fujirebio Diagnostics, Inc.
  • Meridian Bioscience, Inc.
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Savyon Diagnostics Ltd.
  • Sekisui Diagnostics LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-CA17E905E785

The Helicobacter Pylori Diagnostics Market was valued at USD 906.04 million in 2025 and is projected to grow to USD 981.87 million in 2026, with a CAGR of 10.04%, reaching USD 1,770.78 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 906.04 million
Estimated Year [2026] USD 981.87 million
Forecast Year [2032] USD 1,770.78 million
CAGR (%) 10.04%

A definitive overview of Helicobacter pylori diagnostics highlighting clinical implications, diagnostic modalities, patient pathways, and the strategic importance of accurate testing across care settings

Helicobacter pylori remains a central concern in gastrointestinal medicine due to its established role in chronic gastritis, peptic ulcer disease, and as a risk factor for gastric malignancy. Accurate, timely diagnosis is therefore a clinical imperative that affects therapy selection, eradication monitoring, and broader public health efforts. Diagnostics for H. pylori span invasive and noninvasive approaches, each offering distinct trade-offs between sensitivity, specificity, turnaround time, and resource intensity.

Clinical laboratories and care providers must consider test performance characteristics in the context of patient presentation, prior treatment history, and the intended use of results-whether for initial diagnosis, confirmation of eradication, or surveillance for resistance. Recent years have seen the integration of molecular methods alongside traditional histology and culture, while noninvasive antigen and breath tests remain central to outpatient evaluation. These modalities are deployed across varied settings from primary care clinics to large hospital systems, with each setting imposing unique operational constraints and procurement priorities.

As diagnostics evolve, the interplay between laboratory workflows, clinician preferences, and payer policies becomes increasingly consequential. Effective diagnostic strategies require harmonization of specimen collection protocols, quality controls, and clinician education to ensure appropriate test selection and interpretation. Furthermore, diagnostic choice directly influences antibiotic stewardship efforts and downstream clinical outcomes, reinforcing the need for diagnostic pathways that are both clinically robust and operationally feasible.

Transformative technological, operational, and digital shifts reshaping Helicobacter pylori diagnostics with implications for clinical decision making and market dynamics

The diagnostic landscape for Helicobacter pylori is undergoing a rapid transformation driven by advances in molecular technologies, point-of-care instrument miniaturization, and improved noninvasive testing performance. Molecular platforms are expanding from centralized laboratory PCR systems to near-patient isothermal approaches and real-time PCR instruments that provide both detection and antimicrobial resistance markers. At the same time, enhanced immunoassays and high-performance stool antigen tests are refining noninvasive screening and post-treatment confirmation.

Concurrently, endoscopy technology and image-enhancement algorithms are improving visual detection and enabling targeted biopsies that increase diagnostic yield. Artificial intelligence tools are beginning to support lesion recognition and procedural standardization, which, together with enhanced staining and histological techniques, strengthen the role of invasive diagnostics where clinically indicated. These shifts facilitate more precise therapeutic decisions and better alignment with stewardship goals.

Operationally, the movement toward decentralization is reshaping procurement and service delivery. Point-of-care tests reduce time-to-result and can be integrated into ambulatory workflows, while analyzer equipment continues to add throughput and multiplexing capabilities. The convergence of digital health, telemedicine, and laboratory connectivity also supports more seamless result sharing and follow-up, thereby improving adherence to eradication protocols. Taken together, these technological and operational shifts create new commercial and clinical opportunities while raising fresh challenges around validation, quality assurance, and reimbursement.

Assessing how the 2025 United States tariff measures have reshaped supply chains, manufacturing decisions, and procurement strategies across Helicobacter pylori diagnostics

The introduction of United States tariffs in 2025 has produced multifaceted impacts on the diagnostics ecosystem, influencing component sourcing, pricing strategies, and supply chain architecture. Tariff-driven cost pressures on imported consumables, reagents, and analyzer components have led many manufacturers and clinical laboratories to re-evaluate vendor relationships and inventory management practices. In turn, procurement teams have adopted longer lead times and increased buffer stocks to mitigate potential supply disruptions, which affects working capital and operational logistics.

At the product level, tariffs have incentivized local manufacturing or nearshoring initiatives for high-volume consumables and assay kits. Some diagnostic firms responded by qualifying additional domestic contract manufacturers or by relocating assembly lines to jurisdictions less affected by trade barriers. These strategic moves are intended to protect continuity of supply and to reduce exposure to tariff volatility, though they require investment in quality systems, regulatory permits, and supplier audits.

Healthcare providers face competing pressures: the need to maintain clinically validated testing algorithms while managing budgetary constraints. Laboratories and hospitals have scrutinized cost-per-test and total cost of ownership for analyzers, weighing capital acquisition against reagent dependency and service agreement terms. Smaller clinics and ambulatory centers, often with tighter margins, have had to consider consolidated purchasing through group purchasing organizations or long-term supply agreements to preserve access to essential diagnostics.

Regulatory compliance and documentation have become more salient as provenance and traceability requirements increase for domestically sourced assays. Suppliers prioritizing diversified supply chains have also emphasized transparent quality controls and rapid regulatory filings to shorten time-to-market for alternatives. Overall, the tariff environment has catalyzed structural changes across manufacturing, procurement, and clinical adoption pathways, prompting stakeholders to balance resilience investments against near-term operational costs.

Segment-driven insights revealing where test types, product formats, end-user needs, and technology categories converge to shape diagnostic adoption and investment priorities

Insights derived from granular segmentation illuminate where clinical demand converges with technological capability and where strategic investments will yield the greatest returns. Across test types, histology remains a cornerstone in invasive diagnostic workflows and is typically executed with hematoxylin and eosin staining complemented by special stains to enhance organism visualization. Molecular testing has broadened its footprint, with isothermal amplification providing rapid near-patient detection, conventional polymerase chain reaction used in reference laboratories for high-sensitivity assays, and real-time PCR offering quantitation and resistance marker identification. Rapid urease tests retain utility in endoscopy suites and are commonly available as Clo test formats and PyloriTek test variants that prioritize speed and ease of interpretation. Serology continues to play a role in epidemiologic studies and specific clinical contexts through enzyme-linked immunosorbent assays and lateral flow assays, although it is less favored for post-treatment confirmation. Stool antigen testing, delivered via enzyme immunoassays or lateral flow immunoassays, supports noninvasive diagnosis and eradication verification, while urea breath tests, available as 13C and 14C variants, remain a highly accurate noninvasive option often used in primary care and specialist settings.

When evaluating product types, consumables dominate routine testing due to the continual need for kits, reagents, and test strips. Kits span PCR kits for molecular detection, rapid urease test kits tailored for procedural use, serology kits optimized for batch testing, stool antigen test kits suitable for outpatient specimen processing, and urea breath test kits designed for breath analyzer compatibility. Instruments encompass analyzer equipment and endoscopy systems, with analyzer categories including breath test analyzers, immunoassay analyzers, and PCR instruments that vary by throughput, automation level, and connectivity. Endoscopy systems remain critical for invasive diagnostics and therapeutic interventions, driving demand for integrated imaging and biopsy capabilities.

End users introduce operational nuance that shapes product preference and purchasing behavior. Ambulatory care centers, comprised of community health centers and outpatient clinics, prioritize rapid, easy-to-administer noninvasive tests and durable point-of-care solutions. Clinics, whether primary care or specialty-focused, balance cost and clinical performance to support routine screening and follow-up. Diagnostic laboratories, split between commercial and reference laboratories, favor high-throughput molecular instruments and automated immunoassay platforms that enable scalable testing and multiplex capacity. Hospitals, including both large tertiary centers and smaller community facilities, require a hybrid mix: robust endoscopy capabilities for invasive diagnosis and a portfolio of analyzers and consumables that support inpatient and outpatient workflows.

Technology segmentation distinguishes invasive modalities such as culture, histology, and rapid urease testing from noninvasive approaches like antigen testing, breath testing, molecular assays, and serology. Notably, breath testing is contextualized to include both stool antigen test approaches and urea breath tests in applied clinical pathways, reflecting how noninvasive sample types and analytic platforms can overlap in operational deployment. This nuanced segmentation underscores the need for vendors to align product design and commercialization strategies with the distinct workflow requirements of each end-user segment and testing environment.

Regionally differentiated diagnostic dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific revealing adoption, infrastructure, and policy implications for testing strategies

Regional dynamics exert a powerful influence on diagnostic choice, reimbursement, and adoption pathways, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, mature laboratory networks and advanced reimbursement frameworks favor the uptake of high-sensitivity molecular assays and integrated analyzer platforms. Centralized laboratories and reference testing services support complex molecular workflows, while ambulatory care and outpatient clinics increasingly adopt point-of-care solutions to shorten time-to-treatment. This region also emphasizes antimicrobial stewardship programs and post-treatment confirmation protocols that influence test selection.

In Europe, the Middle East & Africa, regulatory diversity and variable healthcare infrastructure create a heterogeneous marketplace. Some countries demonstrate rapid adoption of noninvasive testing and breath analyzers supported by public health screening initiatives, whereas others rely on traditional histology and endoscopy-based diagnostics due to clinician preference or resource constraints. Reimbursement policies and national guidelines in these markets can materially alter the commercial landscape, necessitating localized evidence generation and stakeholder engagement to achieve adoption.

The Asia-Pacific region presents a complex mix of high disease prevalence in certain subregions, growing domestic manufacturing capabilities, and rapid technological adoption. Noninvasive diagnostics such as stool antigen tests and urea breath tests are particularly valuable in primary care settings, and there is notable investment in both molecular platforms and local production of consumables. Private healthcare growth and expanding diagnostic laboratory networks are accelerating the adoption of automated analyzers and multiplex molecular assays, while governmental public health efforts in some countries prioritize screening and eradication programs that influence procurement and implementation strategies.

Company-level perspectives emphasizing product performance, partnership models, supply chain resilience, and clinical evidence strategies that determine competitive positioning in H pylori diagnostics

Competitive dynamics in the diagnostics landscape favor companies that combine robust assay performance with reliable supply chains, regulatory expertise, and clear clinical value propositions. Established instrument manufacturers maintain an advantage through installed base, service networks, and integrated software for result management, while agile molecular firms differentiate via rapid assay development cycles and resistance detection capabilities. Kit and reagent suppliers that can demonstrate reproducible performance across specimen types and that invest in quality certification are positioned to win long-term contracts with commercial and hospital laboratories.

Strategic partnerships and co-development agreements between instrument vendors and assay developers are increasingly common as firms seek to offer end-to-end solutions that simplify adoption for laboratory customers. Contract manufacturing organizations that can scale production while meeting stringent quality standards are valuable partners, particularly in contexts where tariff pressures and supply chain resilience are priorities. Additionally, companies that provide comprehensive training, technical support, and connectivity solutions to integrate test results into electronic health records gain traction with institutional purchasers.

Innovation pipelines focused on multiplexing, resistance genotyping, and simplified sample-to-answer workflows attract attention from both clinicians and procurement teams. Firms that invest in robust clinical validation studies and that engage with key opinion leaders to generate real-world evidence strengthen their market positioning. Finally, organizations that proactively manage regulatory filings and demonstrate compliance across major regions reduce adoption friction and accelerate commercial rollouts.

Actionable strategic recommendations for diagnostic manufacturers, laboratories, and health systems to accelerate adoption, improve resilience, and maximize clinical value of H pylori testing

Industry leaders should consider a set of pragmatic actions to capitalize on emerging diagnostic trends while mitigating operational risk. First, prioritize investment in noninvasive molecular and high-performance antigen assays that streamline workflows and reduce reliance on invasive procedures, while ensuring assays are validated for intended clinical uses. Second, diversify supply chains by qualifying additional suppliers and by evaluating nearshoring or regional manufacturing partnerships to reduce exposure to trade-related disruptions and to improve lead times.

Third, build payer and health system engagement strategies that articulate the clinical and economic value of accurate diagnostics, including the role of testing in reducing unnecessary antibiotic use and in preventing downstream complications. Fourth, develop integrated solutions that pair analyzers with consumable kits and digital connectivity to enhance data flow, enable quality controls, and support clinician decision making. Fifth, invest in antimicrobial resistance testing capabilities and corresponding clinician education to reinforce stewardship and to provide actionable therapeutic guidance.

Sixth, pursue strategic collaborations with endoscopy system providers and laboratory automation partners to create comprehensive diagnostic pathways that align with institutional workflows. Seventh, emphasize regulatory preparedness and rapid evidence generation through multicenter validation studies to facilitate market entry across diverse geographies. Finally, implement flexible commercial models-such as reagent rental, subscription-based pricing, or outcome-linked agreements-to address buyer preferences and to share risk with customers during adoption cycles.

Comprehensive mixed-methods research approach combining expert interviews, workflow analysis, regulatory review, and technology assessment to validate diagnostic insights and implications

The research underpinning this analysis employed a mixed-methods approach that integrates primary qualitative insights with secondary evidence synthesis and technical assessment. Primary research included structured interviews with clinicians, laboratory directors, procurement officers, and industry executives to capture real-world diagnostic workflows, purchasing rationales, and unmet needs. Supplemental site visits and workflow mapping provided contextual understanding of specimen handling, result reporting, and integration points for point-of-care and laboratory systems.

Secondary research encompassed peer-reviewed literature, clinical guidelines, regulatory documentation, and technical product specifications to validate assay performance characteristics and to compare technology platforms. Technology assessments evaluated analytical sensitivity, specificity, turnaround time, throughput, and operational footprint. Regulatory pathways were reviewed across major jurisdictions to identify evidence requirements and approval timelines.

Data triangulation was applied to reconcile discrepancies between primary and secondary sources and to ensure robustness of conclusions. Where available, clinical validation studies and real-world performance data informed assessments of diagnostic utility and suitability for different end-user settings. The methodology also acknowledges limitations, including potential variability in laboratory practices and regional guideline differences, and it emphasizes that insights are intended to support strategic decision-making rather than serve as prescriptive clinical guidance.

Conclusive perspective on the strategic convergence of diagnostic innovation, operational resilience, and clinical stewardship shaping the future of H pylori testing

Diagnostics for Helicobacter pylori are at an inflection point where enhanced molecular capabilities, improved noninvasive tests, and evolving clinical pathways converge to enable more precise patient management. Stakeholders across the ecosystem-manufacturers, laboratories, clinicians, and health systems-must adapt to technological advances while managing supply chain complexities and shifting reimbursement landscapes. Strategic alignment between product design, evidence generation, and end-user needs will be critical to realizing the clinical and commercial potential of next-generation diagnostics.

Looking ahead, success will hinge on the ability to deliver clinically meaningful, operationally sustainable solutions that integrate with care pathways and support antimicrobial stewardship. By prioritizing resilience in sourcing, investing in clinically validated technologies, and engaging payers and providers with clear value propositions, organizations can both improve patient outcomes and secure competitive advantage. The evolving landscape presents significant opportunities for those who combine technical excellence with pragmatic commercialization strategies that respond to regional and end-user heterogeneity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Helicobacter Pylori Diagnostics Market, by Test Type

  • 8.1. Histology
    • 8.1.1. Hematoxylin And Eosin Staining
    • 8.1.2. Special Stains
  • 8.2. Molecular Test
    • 8.2.1. Isothermal Amplification
    • 8.2.2. Polymerase Chain Reaction
    • 8.2.3. Real Time Polymerase Chain Reaction
  • 8.3. Rapid Urease Test
    • 8.3.1. Clo Test
    • 8.3.2. PyloriTek Test
  • 8.4. Serology Test
    • 8.4.1. Enzyme Linked Immunosorbent Assay
    • 8.4.2. Lateral Flow Assay
  • 8.5. Stool Antigen Test
    • 8.5.1. Enzyme Immunoassay
    • 8.5.2. Lateral Flow Immunoassay
  • 8.6. Urea Breath Test
    • 8.6.1. 13C Urea Breath Test
    • 8.6.2. 14C Urea Breath Test

9. Helicobacter Pylori Diagnostics Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Kits
      • 9.1.1.1. PCR Kits
      • 9.1.1.2. Rapid Urease Test Kits
      • 9.1.1.3. Serology Test Kits
      • 9.1.1.4. Stool Antigen Test Kits
      • 9.1.1.5. Urea Breath Test Kits
    • 9.1.2. Reagents
    • 9.1.3. Test Strips
  • 9.2. Instruments
    • 9.2.1. Analyzer Equipment
      • 9.2.1.1. Breath Test Analyzers
      • 9.2.1.2. Immunoassay Analyzers
      • 9.2.1.3. PCR Instruments
    • 9.2.2. Endoscopy Systems

10. Helicobacter Pylori Diagnostics Market, by Technology

  • 10.1. Invasive
    • 10.1.1. Culture
    • 10.1.2. Histology
    • 10.1.3. Rapid Urease Test
  • 10.2. Noninvasive
    • 10.2.1. Antigen Test
    • 10.2.2. Breath Test
      • 10.2.2.1. Stool Antigen Test
      • 10.2.2.2. Urea Breath Test
    • 10.2.3. Molecular
    • 10.2.4. Serology

11. Helicobacter Pylori Diagnostics Market, by End User

  • 11.1. Ambulatory Care Centers
    • 11.1.1. Community Health Centers
    • 11.1.2. Outpatient Clinics
  • 11.2. Clinics
    • 11.2.1. Primary Care Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Diagnostic Laboratories
    • 11.3.1. Commercial Laboratories
    • 11.3.2. Reference Laboratories
  • 11.4. Hospitals
    • 11.4.1. Large Hospitals
    • 11.4.2. Small Hospitals

12. Helicobacter Pylori Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Helicobacter Pylori Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Helicobacter Pylori Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Helicobacter Pylori Diagnostics Market

16. China Helicobacter Pylori Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alpha Laboratories Ltd.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. bioMerieux SA
  • 17.10. Certest Biotec S.L.
  • 17.11. Coris BioConcept
  • 17.12. DiaSorin S.p.A.
  • 17.13. Eiken Chemical Co., Ltd.
  • 17.14. Epitope Diagnostics, Inc.
  • 17.15. F. Hoffmann-La Roche Ltd
  • 17.16. Fujirebio Diagnostics, Inc.
  • 17.17. Meridian Bioscience, Inc.
  • 17.18. Quest Diagnostics Incorporated
  • 17.19. QuidelOrtho Corporation
  • 17.20. Savyon Diagnostics Ltd.
  • 17.21. Sekisui Diagnostics LLC
  • 17.22. Siemens Healthineers AG
  • 17.23. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLO TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PYLORITEK TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 13C UREA BREATH TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY 14C UREA BREATH TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY NONINVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY NONINVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY NONINVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SMALL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SMALL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SMALL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HISTOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY RAPID UREASE TEST, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY SEROLOGY TEST, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY UREA BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY ANALYZER EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY NONINVASIVE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY BREATH TEST, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE HELICOBACTER PYLORI DIAGNOST